EPAS1 and glioblastoma: Specifically, peptide treatment significantly reduced HIF-1α and HIF-2α levels in glioblastoma cells by inducing a drastic inhibition of PI3K/Akt and ERK1/2 signaling cascades, involved in uncontrolled cell proliferation.